Vasily Vasilyevich Kashtalap has a total of 630 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EFFICACY AND SAFETY OF COMBINED LIPID-LOWERING THERAPY IN PATIENTS WITH MIXED DYSLIPIDEMIA: DATA FROM A SURVEY OF EXPERT LIPIDOLOGISTS

    by Vasily V. Kashtalap, Tamara B. Pecherina, Василий Васильевич Кашталап, Тамара Борзалиевна Печерина

    Highlights Mixed dyslipidemia is an aggressive atherogenic phenotype that increases cardiovascular risk. When controlling LDL cholesterol with statins, there remains a high “residual” risk due to hypertriglyceridemia. The use of non‑statin drugs (fenofibrate, omega-3 PUFA) in combinations is limited by doctors’ concerns about safety. Background . Mixed dyslipidemia (MDL) is a common, aggressive, atherogenic lipid phenotype characterized by a simultaneous increase in triglyceride (TG) and very-low-density lipoprotein (VLDL) cholesterol and a decrease in high-density lipoprotein cholesterol (HDL-C) against a background of frequently elevated low-density lipoprotein cholesterol (LDL-C). Despite the dominant role of statins in reducing cardiovascular risk, the residual risk associated with uncontrolled hypertriglyceridemia remains high in patients with MDL, despite statin therapy and the potential achievement of LDL-C goals. This necessitates the use of non-statin medications to correct hypertriglyceridemia. The drugs most frequently prescribed for the correction of hypertriglyceridemia are fenofibrate, a representative of the fibrate class, which has been studied most thoroughly and has shown its effectiveness in correcting residual risk, and the drug omega-3 polyunsaturated fatty acids (LP omega-3 PUFA, Omacor). However, their use in combination with other lipid-lowering medications (statins, ezetimibe, bempedoic acid) raises concerns among physicians in real-world clinical practice due to safety concerns for patients taking this combination. Aim. To evaluate the real-world use of medications for the correction of hyperglycemia (fenofibibrate and/or omega-3 PUFA) and their combinations with other lipid-lowering medications based on a survey of leading Russian lipidology experts. Methods. In November 2025, an interactive survey on the safe use of combination lipid-lowering therapy was conducted as part of a speaker forum of leading lipidology specialists from various regions of Russia (54 experts). Results. The majority (93%) of experts indicate the need for long-term/lifelong/indefinite prescription of triglyceride-lowering medications. Moreover, 87% of experts indicate that “indefinitely” is the correct term. 72% of experts believe that therapy in patients with type 2 diabetes and high LDL-C and TG levels should be initiated with a statin + fenofibrate combination to protect against cardiovascular and microvascular complications. When asked about the proportion of patients requiring three or more lipid-lowering medications as part of routine treatment, 70% of experts indicated a value of up to 20%, while 30% indicated a value of 20–40%. When asked about the frequency of true statin intolerance in routine practice, all experts (100%) responded: up to 10%. In a clinical situation where a patient with high cardiovascular risk, while prescribed rosuvastatin 10 mg, has LDL-C levels reaching 2.0 mmol/L and TG levels remaining at 3.0 mmol/L, 57% of experts would add fenofibrate to therapy and choose a fixed-dose combination (rosuvastatin + fenofibrate, Suprosafen). 11–17% of experts indicated the appropriateness of increasing the rosuvastatin dose to 20 mg, adding ezetimibe to rosuvastatin, or combining fenofibrate and ezetimibe (a triple combination). Conclusion . Thus, leading Russian lipidologists are actively prescribing dual and triple combinations of lipid-lowering drugs aimed at more effectively correcting not only LDL-C levels but also TG and TG-rich particles. The implementation of personalized algorithms taking into account the safety profile will optimize the treatment of patients with mixed DLP and minimize the risks of therapy.

  • Open Access

    Results of validation of the calculator for dynamic risk assessment of heart failure decompensation in patients with low left ventricular ejection fraction

    by N. B. Lebedeva, V. E. Reznikova, D. Yu. Sedykh, Yu. A. Argunova, V. V. Kashtalap, Н. Б. Лебедева, В. Е. Резникова, Д. Ю. Седых, Ю. А. Аргунова, В. В. Кашталап

    Objective: to develop and validate a calculator program for assessing the risk of acute decompensation of heart failure in outpatients with heart failure with reduced left ventricular ejection fraction (HFrEF). Material and methods. A single-center randomized clinical retrospective-prospective study included 652 patients with HFrEF followed at a Heart Failure Center, aged 62.5 (61; 68.5) years; 545 (83.6 %) were men. Of these, 106 patients were selected by simple random sampling to form the validation group. In this group, monthly telephone interviews were conducted by a paramedic from the chronic heart failure center using a structured questionnaire focused on symptoms of fluid retention. The data were entered into a computer-based calculator program, which generated recommendations (emergency hospitalization, unscheduled cardiology visit, or continued follow-up) displayed on the monitor. Validation was performed by retrospectively comparing the calculator’s recommendations with actual adverse events over one year of follow-up. Cases of emergency hospitalization and unscheduled medical visits were recorded. Results. For identifying indications for unscheduled visits, the calculator showed a sensitivity of 85.5 %, specificity of 99.5 %, and area under the ROC curve (AUC) of 0.925. For identifying indications for any medical contact, sensitivity was 73.5 %, specificity 99.7 %, and AUC 0.866. Overall performance for determining the need for any medical contact was: sensitivity 73.5 %, specificity 99.7 %, AUC 0.866. Conclusions. The developed calculator program effectively identifies cases requiring medical attention in various forms, and its recommendations for unscheduled visits or emergency hospitalization are justified in the vast majority of cases.

  • Open Access

    Analysis of determinants and one-year prognostic contribution of quality of life and psychological status indicators in patients with myocardial infarction

    by D. Yu. Sedykh, V. V. Kashtalap, O. L. Barbarash, Д. Ю. Седых, В. В. Кашталап, О. Л. Барбараш

    The aim of this study was to search for significant associations between quality of life and psychological status indicators and the 1-year prognosis of patients with myocardial infarction (MI) and other determinants. Material and methods . The study included 150 patients with non-fatal MI. Psychological status and quality of life indicators, behavioral and socioeconomic factors were assessed. Medical records were collected at discharge. The incidence of a composite cardiovascular outcome was recorded after one year. Using statistical analysis, a search was conducted for significant associative relationships between various variables in the study (methods of logistic linear and binary regression). Results. Subclinical and clinical manifestations of anxiety (frequency 4.7 %) were significantly associated with the lack of higher education odds ratio (OR) – 11.3 (95 % confidence interval (CI) 1.2; 109.6), coronary artery bypass grafting (CABG) after MI – OR 22.9 (95 % CI 1.6; 337.5), low EQ-5D utility index – OR 1.9 (95 % CI 1.6; 2.4); while depression (frequency 6.7 %) was associated with acute stress before MI – OR 5.6 (95 % CI 1.3; 23.2), and the development of a one-year composite cardiovascular outcome – OR 4.5 (95 % CI 1.2; 17.6). According to the quality of life assessment after MI, moderate and severe problems with mobility were identified in 6.7 % of patients, daily activities in 2.0 %, pain in 10.7 %, anxiety/depression in 6.7 %, and there were no problems with self-care. The patients’ health status according to the EQ-VAS scale was 75 (65; 85) points, and the calculated EQ-5D utility index was 1 (1; 1). Low health status score (frequency 41.3 %) was significantly associated with alcohol consumption – OR 2.3 (95 % CI 1.0; 4.9), acute stress before MI – OR 2.3 (95 % CI 1.1; 4.9), low level of physical activity – OR 2.8 (95 % CI 1.0; 7.8)), non-prescription of mineralocorticoid receptor antagonists – OR 2.8 (95 % CI 1.3; 5.9), development of the one-year composite cardiovascular outcome – OR 3.2 (95 % CI 1.2; 8.1); a low EQ-5D score (frequency 16.7 %) was associated with CABG after MI – OR 21.3 (95 % CI 2.2; 211.2) and the development of a one-year composite cardiovascular outcome – OR 3.4 (95 % CI 1.2; 9.1). In patients with MI, quantitative changes in the levels of psychological status indicators (depression, anxiety) and key quality of life parameters (health status according to the EQ-VAS scale and the summary weighted utility index EQ-5D) were not only interrelated with each other at the time of MI, but were also determined by factors preceding MI (social – income, family status, behavioral – acute stress); clinical features associated with MI (patient age at the time of the event, non-use of statins before MI, history of multifocal atherosclerosis, completeness of coronary revascularization in MI or CABG), and also reflected in the 1-year prognosis (development of a composite cardiovascular outcome). Conclusions . In patients with MI, significant associations were confirmed between quality of life and psychological status indicators and one-year prognosis, as well as social, behavioral, and clinical determinants.

  • Open Access

    Results of a phase I clinical trial of a new soluble guanylate cyclase stimulator in healthy volunteers

    by V. V. Bykov, P. D. Yudina, V. V. Larchenko, V. V. Kashtalap, A. V. Bykova, A. Е. Aliforenko, К. Е. Kozhukhovsky, S. А. Stankevich, Е. V. Еfimova, Т. P. Kalashnikova, et al.

    Introduction. Granik ® (the active substance is an indolinone derivative GRS) is a new domestic nitric oxide-independent stimulator of soluble guanylate cyclase (sGC). Stimulation of sGC represents a promising approach to the therapy of cardiovascular diseases caused by thrombosis, particularly in cases where traditional antiplatelet and anticoagulant agents are contraindicated and pose a high risk of bleeding. Granik ® has been in Phase I clinical trials, and this publication is devoted to the evaluation of its safety and pharmacokinetics in healthy volunteers. Aim. The aim of the study was to evaluate the tolerability, safety and pharmacokinetics of Granik ® 20 mg capsules in healthy volunteers after administration under fasting conditions at doses of 20, 40, and 60 mg over a 7-day period. Materials and methods. A double-blind, placebo-controlled study involved 48 healthy male volunteers who received Granik ® at doses of 20, 40, and 60 mg or placebo for 7 days. Tolerability was assessed as good, satisfactory, or unsatisfactory based on subjective data from the volunteers. Safety assessment was based on the analysis of adverse events, laboratory values, ECG data, and vital signs monitoring. GRS plasma concentrations were determined by high-performance liquid chromatography with tandem mass spectrometric detection. Statistical analysis was performed using the R v.3.5 program (Revolution Analytics, USA) and parametric and nonparametric statistics depending on the nature of the data distribution. Results and discussion. Granik ® at doses of 20, 40 and 60 mg demonstrated good tolerability and safety after 7-day administration to healthy volunteers (16 participants in 3 cohorts). Pharmacokinetic parameters varied significantly depending on the dose. The maximum plasma concentration ( C max ) of the GRS compound was reached in 0.5–1.5 h. When Granik ® was administered at a dose of 60 mg, the GRS substance remained in plasma for a long time: the half-elimination period ( t 1/2 ) was 24.61 ± 10.40 h. When Granik ® was administered at doses of 20 and 40 mg, elimination from plasma was accelerated: the half-elimination period decreased to 4.34 ± 3.61 h and 3.69 ± 5.09 h, respectively. The accumulation coefficient of the GRS substance did not statistically significantly differ when Granik ® was administered in the dose range of 20–60 mg per day. Conclusion. Granik ® demonstrated good tolerability and a favorable safety profile when administered as a course. These results justify the transition to the next phase of clinical trials of Granik ® .

  • Open Access

    COMBINATION LIPID-LOWERING THERAPY WITH ROSUVASTATIN AND EZETIMIBE IN THE PREVENTION OF CARDIOVASCULAR COMPLICATIONS (CASE SERIES FROM CLINICAL PRACTICE)

    by Василий Васильевич Кашталап, Daria Yu. Sedykh, Екатерина Альбертовна Павлова, Дарья Юрьевна Седых

    Highlights Combined lipid–lowering therapy, including rosuvastatin and ezetimibe (the true fixed combination is ZENON®), has been proven effective and safe in the prevention of cardiovascular complications in patients with atherosclerotic pathology, including after acute cardiovascular disasters, with diabetes mellitus and the elderly. There are few data on the experience of using combined lipid-lowering therapy (statin and ezetimibe) in patients with aortic stenosis, which actualizes the demonstration of cases from real clinical practice in publications. Abstract This article presents our clinical experience and reviews existing clinical studies evaluating the efficacy and safety of combination lipid-lowering therapy with a statin and a cholesterol absorption inhibitor (ezetimibe) for the prevention of cardiovascular complications associated with atherosclerosis. Clinical examples of outpatient management of patients with atherosclerosis and concomitant cardiovascular diseases using a fixed-dose combination of rosuvastatin at the maximum tolerated dose and ezetimibe (ZENON®) are presented. These results demonstrated positive results in terms of cardiovascular complication prevention over a 9-month follow-up period, achievement of target lipid profile values, and good tolerability of this combination.

  • Open Access

    HOSPITAL MORBIDITY AND OUTCOMES OF INPATIENT TREATMENT IN CARDIAC PATIENTS WITH NEW CORONAVIRUS INFECTION

    by Evgeny D. Bazdyrev, Liudmila S. Gofman, Alexey V. Alekseenko, Sergey A. Makarov, Vasily V. Kashtalap, Olga V. Gruzdeva, Tatyana A. Trushkina, Artur V. Sadovnikov, Евгений Дмитриевич Баздырев, Людмила Сергеевна Гофман, et al.

    Highlights The article presents the results of analysis of hospital morbidity and mortality in patients with cardiovascular diseases receiving specialized medical care at the Department of Infectious Diseases of the Kuzbass Clinical Cardiology Dispensary named after Academician L.S. Barbarash.   Aim. To analyze hospital morbidity and mortality in patients with new coronavirus infection (NCI) who received specialized medical care at the Department of Infectious Diseases of the Kuzbass Clinical Cardiology Dispensary named after Academician Barbarash. Methods . The object of the study were the reports of the head of the Department of Infectious Diseases regarding patients with circulatory system diseases (CSD) and NCI receiving care at the Kuzbass Cardiology Center for the period from 10.21.2020 to 30.06.2022. The subject of the retrospective study were the types of CSD and mortality (ICD-10 code) in treated patients. The unit of analysis – treated patients with CSD (18 years and older) and NCI (U07.1 and U07.2). Results . Data of 1 248 patients with CSD and NCI were analyzed. The highest number of such cases occurred in 2021, accounting for more than half of all patients treated at the Department. More than half of the patients were hospitalized with acute coronary artery disease (CAD), less than a quarter of the patients were hospitalized with chronic CAD and heart failure. Acute coronary syndrome (ACS) was verified in 38.9% of patients, stroke in 22.4% of patients, and pulmonary embolism in 1.8% of patients (n = 22). Patients were more often admitted with acute (primary) myocardial infarction (MI) and unstable CAD (17.6% and 15%, respectively), and half as often with recurrent MI (6.3%). Less than 40% of patients were hospitalized due to chronic CSD, among which prevailed chronic CAD and decompensated chronic heart failure (CHF) (19.7%). Mortality was 16%, mortality within 24 hours was 2.5%. The mean age of the deceased patients was 72.69 ± 12.22 years. The proportion of patients of working age who died was 10.8 times lower than that of patients older than working age. On average, women were 1.1 times more likely to die during the analyzed period. Acute CSD (32.3%), chronic CSD (33.5%) and stroke (34.2%) caused death at an equal rate. Conclusion . Patients with ACS and stroke were the majority of treated patients. Patients were more often admitted with primary MI and unstable CAD, and half as often with recurrent MI. The most predominant chronic CSD were chronic CAD and decompensated CHF. One sixth of all treated patients died. Acute and chronic CSD and stroke caused death at an equal rate.

  • Open Access

    GENE-GENE INTERACTIONS OF POLYMORPHIC LOCUSES OF LIPID AND CARBOHYDRATE METABOLISM GENES ASSOCIATED WITH THE MYOCARDIAL INFARCTION RISK IN PATIENTS WITH OBESITY

    by Mariya V. Khutornaya, Oksana N. Hryachkova, Anna V. Sinitskaya, Maxim A. Asanov, Alena O. Poddubnyak, Maxim Yu. Sinitsky, Vasiliy V. Kashtalap, Мария Владимировна Хуторная, Оксана Николаевна Хрячкова, Анна Викторовна Синицкая, et al.

    Highlights Combined interactions of polymorphic loci in lipid and carbohydrate metabolism genes in patients with myocardial infarction) and obesity were studied in the presented research. It was hypothesized that these interactions can explain the individual differences in the risk of cardiometabolic disorders due to modulation of their manifestation. Aim. To investigate the patterns of gene-gene interactions of polymorphic loci in lipid and carbohydrate metabolism genes in patients with myocardial infarction depending on the presence of comorbid obesity. Methods. 146 patients with acute myocardial infarction, divided into groups with and without obesity were examined. The control cohort consisted of 300 apparently healthy residents of the region. DNA was isolated from peripheral blood using phenol-chloroform extraction. Genotyping of 12 polymorphic variants in 8 genes involved in the regulation of lipid and carbohydrate metabolism was performed using the TaqMan assay on a ViiA™ 7 analyzer. Gene-gene interaction analysis was performed using MDR v.3.0.2. Results. In this study, significant associations between the IGF1R gene rs2229765 polymorphism and APOE gene rs7412 polymorphism associated with an increased obesity risk in myocardial infarction patients were identified. Using the MDR assay, key gene-gene interaction models were identified: a four-locus model associated with myocardial infarction risk (rs1137101 LEPR – rs1137100 LEPR – rs1042031 APOB – rs6725189 APOB ) and a twelve-locus model associated with obesity risk including all analyzed polymorphic loci. The greatest entropic contributions to myocardial infarction risk were found to be made by APOB gene rs6725189 polymorphism, LEPR gene rs1137100 polymorphism, and LIPC gene rs1800588 polymorphism, while a pronounced synergistic effect was detected for the rs6725189-rs1042031 ( APOB ) pair. In the obesity risk model, the greatest individual contributions were observed for APOE gene rs7412 polymorphism and IGF1R gene rs2229765 polymorphism, while strong synergistic interactions were observed for pairs including LEPR gene rs1137100 polymorphism. Conclusion. Assessment of gene-gene interactions revealed that the combined pathogenetic effects of polymorphic loci of lipid and carbohydrate metabolism genes exceed their independent contributions. This finding can be used to assess the genetic risk of myocardial infarction and develop personalized approaches to the prevention and management of patients with cardiometabolic comorbidity.

  • HEALTHY LIFE EXPECTANCY IN CENTRAL ASIA: THE ATHEROGENIC ENVIRONMENT AND REGIONAL FEATURES OF CARDIOMETABOLIC PREVENTION

    by Aleksandr V. Martynenko, Andrey N. Ilnitski, Elena A. Voronina, Vasily V. Kashtalap

    Highlights Within a shared urban environment in Central Asia, three distinct ethnocultural groups (Uzbeks, Russians and Koreans) display a broadly similar cardiometabolic phenotype characterized by excess body weight, insulin resistance and triglyceride-driven atherogenicity. In men with arterial hypertension and type 2 diabetes, a more pronounced residual-risk profile is observed, including higher triglycerides, non-HDL cholesterol, a higher atherogenic index of plasma and lower eGFR. The findings support the need for environment-focused preventive interventions (nutrition, physical activity, urban design) and for intensifying lipid-lowering therapy already in midlife, in order to increase healthy life expectancy in the region. Background . In Central Asian countries, rising life expectancy coexists with persistently high cardiovascular mortality. It is assumed that an atherogenic environment (energy-dense diets, low everyday physical activity, heat exposure, air pollution and chronic stress) amplifies insulin resistance and triglyceride-driven atherogenicity in middle-aged and older adults. Aim. To characterize the lipid and metabolic profile of Central Asian residents aged ≥ 50 years; to assess indices of triglyceride-mediated atherogenicity and insulin resistance and their association with sex, arterial hypertension (AH), type 2 diabetes (T2D), carotid atherosclerosis and statin use; and to demonstrate that the impact of a shared urban environment outweighs ethnic differences. Methods. We conducted a single-centre cross-sectional study in Tashkent (December 2024 – August 2025; cut-off date 4 September 2025). We enrolled 167 participants (Uzbeks n = 108, Russians n = 46, Koreans n = 13; 66% women) aged ≥ 50 years, born and living in Central Asian countries. Anthropometry, biochemical and hematological tests, and carotid duplex ultrasonography were performed. The following indices were calculated: non-HDL-C, AIP, TG/HDL-C, remnant cholesterol, HOMA-IR, QUICKI, TyG and eGFR (CKD-EPI 2021). Statistical analyses included the t-test/Mann–Whitney test, Fisher’s exact test and Spearman’s ρ; multiple testing was controlled using Benjamini–Hochberg FDR correction; α = 0.05. Results. Across all ethnic groups, women showed a more favorable lipid profile (higher HDL-C, lower Castelli I/II, AIP and TG/HDL-C), whereas men more often exhibited a combined dyslipidemia phenotype (elevated TG, non-HDL-C and AIP). Among Uzbek men, HOMA-IR 5.0 ± 3.7 and QUICKI 0.33 ± 0.03 reflected marked insulin resistance; similar patterns were observed in the Russian and Korean strata. The presence of T2D was associated with higher glucose, insulin, HOMA-IR, AIP, non-HDL-C and triglycerides, and with lower eGFR in all sex-ethnic subgroups. In patients with AH, BMI, TG, AIP and HOMA-IR were higher. Under statin therapy, total cholesterol/LDL-C/non-HDL-C were reduced, but AIP and TG/HDL-C remained elevated; fewer than 40% of treated patients achieved LDL-C targets. Correlation analysis demonstrated robust positive associations of AIP, TG/HDL-C and non-HDL-C with HOMA-IR and TyG, and inverse correlations with HDL-C. The direction of effects was preserved after stratification by sex and ethnicity. Conclusions. Within a common urban environment in Central Asia, triglyceride-driven atherogenicity on a background of insulin resistance predominates, with a less favorable phenotype in men and in those with T2D and AH, irrespective of ethnic origin. Practical priorities include expanded lipid assessment (non-HDL-C, remnant-C, AIP, TyG), intensification of lipid-lowering therapy (high-intensity statins ± ezetimibe/EPA), early detection of insulin resistance and environment-focused preventive measures (nutrition, physical activity, urban environment). Such a strategy at both clinical and community level has the potential to increase healthy life expectancy in the region.

  • Open Access

    Current hypertension treatment possibilities and tactics in patients with comorbidities. The role of selective imidazoline receptor agonists. Expert opinion

    by T. V. Pecherina, G. A. Chumakova, Yu. I. Grinshtein, O. Yu. Donirova, N. V. Zakharchuk, V. V. Kashtalap, T. A. Petrichko, L. I. Syromyatnikova, O. V. Fedorishina, S. М. Cherepenin, et al.

    Hypertension (HTN) is a serious public health problem. Despite advances in diagnosis and public awareness, the percentage of controlled cases remains low, especially among men and the elderly. The main challenges are related to comorbidities such as obesity, diabetes, chronic kidney disease, and obstructive sleep apnea, which worsen the prognosis and increase the risk of cardiovascular events. The approach to HTN treatment should be individualized and take into account specific disease phenotypes and comorbidities. It is important to identify patients with increased sympathetic nervous system activity, as this group experiences the greatest difficulties in blood pressure control. Moxonidine, a centrally acting agent, selectively stimulates imidazoline receptors in the brain, causing a decrease in sympathetic activity and effective reduction in blood pressure. The need for a personalized approach to HTN therapy is driven by the growing number of patients with multiple comorbidities and complex pathogenesis. New approaches, including early initiation of combination therapy and targeted management of metabolic risk factors, will reduce cardiovascular morbidity and mortality. Moxonidine plays a key role within antihypertensive medications due to its unique mechanism of action and ability to positively impact a wide range of HTN-related pathologies

  • Open Access

    DIFFICULTIES IN MANAGING PATIENTS WITH TYPE 2 DIABETES, ACUTE CORONARY SYNDROME, AND MULTIFOCAL ATHEROSCLEROSIS IN REAL CLINICAL PRACTICE (BASED ON A CLINICAL CASE)

    by Yuliya E. Nikiforova, Ольга Константиновна Кузьмина, Василий Васильевич Кашталап

    Highlights Diabetes mellitus is a severe, rapidly progressing disease. In the absence of high patient compliance, it is often associated with multifocal atherosclerosis, renal dysfunction, and acute cardiovascular events (myocardial infarction and stroke). Prevention of these complications and morbid conditions requires high patient commitment to the prescribed therapy, which is the main goal of managing a patient with diabetes mellitus.   Absract The purpose is to present, by the example of a clinical case, relevant information for practicing physicians about the unfavorable, progressive, course of multifocal atherosclerosis in a patient with insufficient therapy of type 2 diabetes mellitus and having insufficient compliance with the prescribed drug therapy. The article describes a difficult case for doctors of an atypical course of acute coronary syndrome in such a patient and difficulties in choosing an effective method of myocardial revascularization. The presented clinical case illustrates the existing difficulties in managing patients with type 2 diabetes mellitus and atherosclerosis in real clinical practice. Attention is drawn to the need for early initiation of disease-modifying therapy and organ protection in type 2 diabetes mellitus, as well as to the need for screening for low adherence to prescribed treatment in such patients and its timely correction at all stages of treatment using digital technologies.